FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions

FDA approvals of gene therapies began slowly and were concentrated within a few early modalities, but recent years have seen a marked acceleration across RNA-based agents, viral and non-viral in vivo platforms, and ex vivo genetically modified cell therapies. This expansion reflects the maturation of gene therapy into a diverse therapeutic class while revealing scientific, regulatory, and economic challenges that traditional development paradigms cannot fully accommodate. In response, FDA has introduced platform-aligned, risk-based initiatives-including the plausible mechanism framework, CMC flexibility initiative, and advanced manufacturing technologies program-to support individualized, mechanistically targeted, and potentially curative products. Persistent issues such as high upfront costs, manufacturing complexity, and payer constraints underscore the need for sustainable development and access models. Mechanistic and model-informed drug development, increasingly supported by AI/ML-enabled analytics, is becoming central to dose selection, safety evaluation, and durability prediction. These scientific, regulatory, and clinical-pharmacology perspectives define the evolving landscape of FDA gene therapy approvals and outline future directions needed to ensure durable benefit, equitable access, and long-term safety as genetic medicines expand into broader patient populations.